S

Solaris Clinical Research | Meridian, ID

Research site
(Unclaimed)
Location
1525 E. Leigh Field Drive 100, Meridian, Idaho, United States of America
Site insights

Top conditions

Type 2 Diabetes Mellitus (18 trials)

Diabetes Mellitus (17 trials)

Obesity (10 trials)

COVID-19 (7 trials)

Overweight (6 trials)

Top treatments

Tirzepatide
LY3298176
Metformin
Bococizumab
Semaglutide
Sugar
BI 456906
Testosterone
K-877
Triglyceride

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

17 of 49
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD....

Active, not recruiting
Atopic Dermatitis
Drug: Difamilast

This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight i...

Enrolling
Obesity
Drug: Semaglutide
Drug: Placebo

This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling
Type 2 Diabetes
Drug: Placebo
Drug: Cagrilintide

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling
Type 2 Diabetes
Drug: Tirzepatide
Drug: Cagrilintide

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 dia...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Enrolling
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Semaglutide
Locations recently updated

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo
New

The main purpose of this study is to determine if combining tirzepatide with the mibavademab will result in more weight loss in adult participants th...

Begins enrollment this month
Obesity
Drug: Mibavademab-Placebo
Drug: Mibavademab

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide
Locations recently updated

The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide
Locations recently updated

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Enrolling
COVID-19
Influenza
Biological: Placebo
Biological: Influenza and COVID-19 Combination B

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune s...

Enrolling
Shingles
Human
Biological: Selected Vaccine Candidate group (Dose level, Schedule)
Biological: Shingrix - SSB

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Enrolling
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo
Status recently updated

This study is open to adults who are at least 18 years old and havea body mass index (BMI) of 30 kg/m² or more, ora BMI of 27 kg/m² or more and at le...

Enrolling
Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to los...

Active, not recruiting
Obesity
Drug: Liraglutide
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting
Lower Respiratory Tract Illness
Biological: Placebo
Biological: RSVpreF

Trial sponsors

Pfizer logo

Pfizer (12 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems